Effect of Topical Nepafenac on Central Foveal Thickness following Panretinal Photocoagulation in Diabetic Patients

Table 2

BCVA and lines of deterioration in both groups.

	Pre-PRP	1 month	2 months	4 months	6 months	Lines lost of BCVA at 6 months
Nepafenac group (logMAR) mean ± SD	0.06 ± 0.06	0.09 ± 0.06	0.09 ± 0.06	0.11 ± 0.05	0.11 ± 0.04	1.0 ± 1.0
Control group (logMAR) mean ± SD	0.07 ± 0.07	0.14 ± 0.08	0.17 ± 0.08	0.19 ± 0.09	0.18 ± 0.08	1.96 ± 1.07
value	0.432	0.011	0.0051	0.0066	0.0072	0.0054